Researcher
Nick Devoogdt
- Keywords:Medicine, Applied biological sciences, biotechnology
- Disciplines:Cancer therapy, Radiopharmacy, Biomarker evaluation, Nuclear imaging, Molecular diagnostics, Medical molecular engineering of nucleic acids and proteins, Medical biotechnology diagnostics, Applied immunology, Non-clinical studies, Industrial molecular engineering of nucleic acids and proteins, Cancer diagnosis
Affiliations
- Medical Imaging (Research group)
Member
From1 Jan 2011 → Today - Supporting clinical sciences (Department)
Member
From1 Oct 2021 → Today - Supporting clinical sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2021 - Supporting clinical sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Supporting clinical sciences (Department)
Member
From1 Mar 2013 → 31 Dec 2017 - Medical Imaging and Physical Sciences (Department)
Member
From1 Mar 2013 → 31 Dec 2013 - Medical Imaging and Physical Sciences (Department)
Member
From1 Oct 2007 → 30 Sep 2009 - Cellular and Molecular Immunology (Research group)
Member
From1 Oct 1999 → 30 Sep 2007 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 1997 → 28 Feb 2013
Projects
1 - 10 of 34
- Exploiting Peptides as Protein Binders, Modulators, Inhibitors and Biomaterials for Imaging and Therapy [Exploit-PeptIT]From1 Mar 2024 → TodayFunding: BOF - projects
- Development of a bispecific immunotracer against CD8 and CD69 for enhanced non-invasive imaging of immune responses during anti-cancer immunotherapyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Development of automated enzyme-mediated bioconjugations as a technology to produce smallprotein-based radiopharmaceuFrom1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- MATRACs: Membrane Anchoring TRAfficking ChimerasFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- INVISIBLE: Investigation and inhibition of Epstein-Barr Virus immune evasion by BILF1-modulating nanobodiesFrom1 Nov 2022 → TodayFunding: FWO junior postdoctoral fellowship
- SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancerFrom1 Nov 2022 → TodayFunding: BOF - projects
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → TodayFunding: IOF - technology validation in real environment
- IOF POC Project SYNALI : Development and application of a Synthetic Nanobody LibraryFrom1 Jan 2022 → TodayFunding: IOF - technology concept exploration
- Nanobody-based AXL targeting and combination treatment for acute myeloid leukemia and multiple myelomaFrom1 Jan 2022 → TodayFunding: FWO research project (including WEAVE projects)
- Evaluation of an in vivo pre-targeting approach for targeted radionuclide therapy of cancer using clickable anti-B7-H3 single domain antibodies.From1 Nov 2021 → TodayFunding: FWO fellowships
Publications
1 - 10 of 110
- Sustained release of a human pd-l1 single-domain antibody using peptide-based hydrogels(2024)
Authors: Julie Heremans, Robin Maximilian Awad, Jessica Bridoux, Thomas Ertveldt, Vicky Caveliers, Annemieke Madder, Richard Hoogenboom, Nick Devoogdt, Steven Ballet, Sophie Hernot, et al.
- Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma(2024)
Authors: Odrade Gondry, Vicky Caveliers, Catarina Xavier, Marian Vanhoeij, Guy Verfaillie, Christel Fontaine, Katrien Glorieus, Jacques De Greve, Sofie Joris, Ine Luyten, et al.
Pages: 178-184 - In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4+ T cells(2023)
Authors: Robin Maximilian Awad, Yannick De Vlaeminck, Fien Meeus, Thomas Ertveldt, Katty Zeven, Hannelore Ceuppens, Cleo Goyvaerts, Magali Verdonck, Gustavo Salguero, Geert Raes, et al.
Pages: 1-13 - Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody(2023)
Authors: Maxime Nachit, Christopher Montemagno, Romain Clerc, Mitra Ahmadi, François Briand, Sandrine Bacot, Nick Devoogdt, Cindy Serdjebi, Catherine Ghezzi, Thierry Sulpice, et al.
- Case Study #3: Antibody Fragments in Radiopharmaceutical Therapy(2023)
Authors: Cyprine Neba Funeh, Parinaz Asiabi, Matthias D'Huyvetter, Nick Devoogdt
Pages: 253-273Number of pages: 20 - Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury(2023)
Authors: Raf Van Campenhout, Timo W M De Groof, Prashant Kadam, Brenda R. Kwak, Serge Muyldermans, Nick Devoogdt, Mathieu Vinken
Pages: 371 - Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine(2023)
Authors: Thomas Ertveldt, Sofie Meulewaeter, Yannick De Vlaeminck, Oscar Olarte, Katrijn Broos, Serge Van Calenbergh, Stephanie Bourgeois, Joke Deprez, Yves Heremans, Cleo Goyvaerts, et al.
Pages: 5483-5500 - Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT(2023)
Authors: Katty Zeven, Timo W M De Groof, Hannelore Ceuppens, Robin Maximilian Awad, Thomas Ertveldt, Wout De Mey, Fien Meeus, Geert Raes, Karine Breckpot, Nick Devoogdt
- Safety assessment of fluorescently labeled anti-EGFR Nanobodies in healthy dogs(2023)
Authors: Nayra Cristina Herreira do Valle, Simone Janssen, Marcus Stroet, Sofie Pollenus, Sonja Van den Block, Nick Devoogdt, Jens Debacker, Sophie Hernot, Hilde de Rooster
- Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)(2023)
Authors: Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, et al.
Pages: 1378-1384
Patents
1 - 10 of 10
- Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases (Inventor)
- Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells (Inventor)
- Anti-vcam-1 nanobodies (Inventor)
- Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer (Inventor)
- Anti lag3 vhhs and their use (Inventor)
- Radiolabelled antibody fragments for use in treating cancer (Inventor)
- Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- Radiolabelled antibody fragments for use in treating cancer (Inventor)
- Anti-dpp6 chimeric antigen receptor bearing regulatory t cells (Inventor)
- Anti lag3 vhhs and their use (Inventor)